(Q44907080)

English

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

0 references

1 reference

based on heuristic

inferred from title

Eugene V McCloskey

1

object named as

Eugene V McCloskey

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3

object named as

Anders Oden

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

10

object named as

John A Kanis

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

8

object named as

Roman Lorenc

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

E Michael Lewiecki

7

object named as

E Michael Lewiecki

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Helena Johansson

2

object named as

Helena Johansson

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

9

object named as

Cesar Libanati

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Matt Austin

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Ethel Siris

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Andrea Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

publication date

1 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1480-1486

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Denosumab in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Vertebral fracture assessment using a semiquantitative technique.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Pitfalls in the external validation of FRAX.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.1606

21 January 2018

Identifiers

10.1002/JBMR.1606

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44907080&oldid=1857592782"